Peter MacCallum Cancer Centre, Affymetrix collaborate

Five-year collaboration to analyze genomic information across large patient samples.
Register for free to listen to this article
Listen with Speechify
0:00
1:00
SANTA CLARA, Calif.—Affymetrix Inc. announced that it entered into a five-year collaboration with the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne, Australia, to ana­lyze genomic information across large patient samples. Under terms of the agreement, Peter Mac researchers will use Affymetrix GeneChip microarray technology for translational research projects, beginning with studies on ovarian cancer and carcinoma of unknown primaries.
 
Peter Mac researchers will use Affymetrix GeneChip technology to per­form large-scale clinical studies. The Affymetrix technology will enable them to more rapidly discover RNA and DNA patterns that can better classify, man­age and treat complex diseases.
 
"We are excited about the oppor­tunities created by the Translational Medicine Program, particularly the chance to apply new technologies to help us answer important clinical ques­tions," says Dr. David Bowtell, director of research at the Peter MacCallum Cancer Centre. "We are keen to help our collaborators across Australia gain access to Affymetrix technology, as we continue to develop as a major center for cancer genom­ics and genetics. We also see the pro­gram providing opportunities to interact with other centers worldwide that are involved in translational research."
 
Affymetrix collaborates with aca­demic institutions, advocacy groups and the pharmaceutical and diagnos­tics community through its Translational Medicine Program to develop molecular signatures for improving patient care. Affymetrix GeneChip microarray technol­ogy helps researchers to diagnose and tailor treatments for individual patients by identifying and measuring the genet­ic information associated with complex diseases.
 
The Translational Medicine Program complements the Powered by Affymetrix program, which enables com­panies to license GeneChip technology to create innovative, custom-designed microarray products based on signa­tures such as those of its translational medicine partners. This technology is already being used in many applica­tions, including diagnostics, forensics, and animal, industrial and food testing.

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Image Alt Text	A laboratorian wearing blue gloves places a PCR sample into a real-time PCR thermocycler, the model shown is blue and white with a large digital screen.
From primer design to sample preparation, explore comprehensive strategies to optimize PCR throughput and reproducibility.
Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue